Indivior Pharmaceuticals (INDV) EBITDA (2024 - 2026)

Indivior Pharmaceuticals has reported EBITDA for 3 years, with the latest figure at $160.0 million in Q2 2026.

• On a quarterly basis, EBITDA rose 122.22% year-over-year to $160.0 million in Q2 2026; TTM through Jun 2026 was $421.0 million, a 92.24% increase from a year earlier, with the FY2025 full-year figure at $262.0 million, up 589.47% from the prior year.
• EBITDA was $160.0 million for Q2 2026 at Indivior Pharmaceuticals, up from $137.0 million in the prior quarter.
• The five-year high for EBITDA was $160.0 million in Q2 2026, with the low at -$118.0 million in Q2 2024.
• Average EBITDA over 3 years is $59.7 million, with a median of $69.0 million recorded in 2025.
• The largest YoY upside for EBITDA was 161.02% in 2025 against a maximum downside of 12.0% in 2025.
• Over 3 years, EBITDA stood at $46.0 million in 2024, then soared by 76.09% to $81.0 million in 2025, then jumped by 97.53% to $160.0 million in 2026.
• The last three EBITDA figures came in at $160.0 million (Q2 2026), $137.0 million (Q1 2026), and $81.0 million (Q4 2025), per Business Quant data.